A proposed class action against AbbVie Inc. and seven biosimilar makers shows potential fault lines of biosimilar patent litigation settlements and intensifies the pressure on AbbVie's Humira (adalimumab) patent estate.
The UFCW Local 1500 Welfare Fund, the largest grocery-worker union in New York state, filed a March 18 suit in the US District Court for the Northern District of Illinois against AbbVie and the companies with whom it has inked patent settlement and licensing deals